Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price & Analysis
Amylyx Pharmaceuticals, Inc. (AMLX) closed at USD 27.65 on Thursday, October 15, 2026, up 2.29% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 27.03; the Oct 15, 2026 session ranged USD 27.45–28.34 on volume of 882,540 shares. Market capitalization is $3.47B, with a 52-week range of USD 10.83–41.14 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/AMLX.md
Key facts (AMLX)
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 42.36 (range 20–57).
- Total return with dividends: 1Y +82.3% vs S&P 500 +18.1%; 5Y +53.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.37, revenue estimate $38K.
Analysts (AMLX)
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 42.36 (low 20, high 57).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Citigroup | Target raised | Buy | $32 → $39 |
| 2026-08-27 | Guggenheim | Target raised | Buy | $55 → $57 |
| 2026-08-19 | Mizuho | Target raised | Outperform | $30 → $42 |
| 2026-08-19 | Guggenheim | Target raised | Buy | $40 → $55 |
| 2026-08-19 | Baird | Target raised | Outperform | $28 → $52 |
| 2026-08-18 | HC Wainwright & Co. | Target raised | Buy | $34 → $55 |
| 2026-08-17 | Mizuho | Target raised | Outperform | $24 → $30 |
| 2026-08-03 | Citigroup | Target raised | Buy | $20 → $26 |
| 2026-07-20 | Mizuho | Target raised | Outperform | $21 → $24 |
| 2026-06-25 | Guggenheim | Target raised | Buy | $30 → $40 |
Total return (dividends reinvested) (AMLX)
| 1Y (from 2025-10-16) | 5Y (from 2022-01-03) | |
|---|---|---|
| Total return | +82.3% | +53.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +82.6% | +9.3% |
| Volatility (annualized) | 75.8% | 116.5% |
| Max drawdown | -32.3% (Aug 2026→Oct 2026) | -96.0% (Jan 2023→Jun 2024) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 27.65 |
|---|---|
| Change | ▲ 2.29% (up) |
| Previous Close | USD 27.03 |
| Open | USD 27.68 |
| Day Range | USD 27.45 – 28.34 |
| 52-Week Range | USD 10.83 – 41.14 |
| Volume | 882,540 shares |
| Market Cap | $3.47B |
| Exchange | NMS |
Technical Analysis (AMLX)
Nexqual's technical model rates AMLX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 36.02 (neutral) |
| vs SMA50 | Below (USD 30.64) |
| MACD | -1.03 (negative) |
Analyst Ratings (AMLX)
Wall Street analysts rate AMLX "Buy" based on 12 analysts, with a mean price target of USD 42.36 (range USD 20–57), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 42.36 |
| High Target | USD 57 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (AMLX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $37,820 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.39 vs est -0.36 ▼ miss |
| 2026-03-31 | USD -0.37 vs est -0.34 ▼ miss |
| 2025-12-31 | USD -0.3 vs est -0.34 ▲ beat |
| 2025-09-30 | USD -0.37 vs est -0.43 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (AMLX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.73% |
| Debt / Equity | 0.02 |
| Current Ratio | 12.12 |
| Total Cash | $250.76M |
| Total Debt | $5.25M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (AMLX)
Nexqual rates Amylyx Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $251M cash vs $5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$123M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -75%, ROA -44.1% |
Ownership (AMLX)
| Insider Ownership | +7.16% |
|---|---|
| Institutional Ownership | +92.43% |
| Shares Outstanding | 125.51M |
| Float | 97.28M |
| Short % of Float | +12.64% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (AMLX)
Amylyx Pharmaceuticals, Inc. is led by Joshua B. Cohen (age 33), Co-Founder, Co-CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| Co-Founder, Co-CEO & Director | Joshua B. Cohen (age 33) |
|---|---|
| Co-CEO & Director | Justin B. Klee (age 34) |
| Chief Financial Officer | James M. Frates (age 58) |
Major Backers & Investors (AMLX)
Notable institutional backers of Amylyx Pharmaceuticals, Inc. include FMR, LLC, Fidelity, Perceptive Advisors Llc, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 15.01% |
| Fidelity | 10.1% |
| Perceptive Advisors Llc | 7.48% |
| TCG Crossover Management, LLC | 5.6% |
| Commodore Capital Lp | 5.07% |
| Jupiter Topco LLC | 4.7% |
| Saturn V Capital Management LP | 4.15% |
| Morgan Stanley | 2.81% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.23% |
| Vanguard Group | 6.62% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 79.94 | ▲ 1.8% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt